Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Development of a PET Radiotracer for Imaging GPR6 in the Brain

FY 2025-26

Summary
More than 110,000 people in Canada are currently living with Parkinson’s disease (PD), and this number is expected to rise sharply as our population ages. PD is a brain disorder that causes tremors, stiffness, and difficulty with movement due to the loss of dopamine producing cells. Current medications improve symptoms temporarily but cause side effects after prolonged use, limiting their benefits, and they do not slow or stop the disease. This has created an urgent need for new treatments that work through different biological pathways. One promising target is a protein in the brain called G protein-coupled receptor 6 (GPR6), which helps control movement and is thought to be overactive in PD. CVN424 is a new experimental drug that “turns down” GPR6 activity and is currently being tested in clinical trials as a way to improve symptoms without the side effects of classic dopamine-based drugs. However, we currently have no way to see, in a living brain, how much CVN424 actually reaches its target or how long it stays there. Positron emission tomography (PET) is a powerful imaging technique that can show where a drug goes in the body using tiny amounts of a radiopharmaceutical. In this project, we will attach a small amount of radioactive fluorine-18 (18F) to CVN424 to create a PET tracer, [18F]CVN424, and test how it behaves in live mice. This will allow us to measure its uptake in the brain and its binding to GPR6. If successful, this tracer could speed up the development of new GPR6-targeted drugs and eventually help select and monitor patients in future clinical trials.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
573049
Name
Xu Wan Li
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a PET Radiotracer for Imaging GPR6 in the Brain
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cvn424; Dopamine; G Protein-Coupled Receptor 6 (Gpr6); Neurodegeneration; Parkinson'S Disease; Pet Imaging; Radiopharmaceutical
Abstract
More than 110,000 people in Canada are currently living with Parkinson’s disease (PD), and this number is expected to rise sharply as our population ages. PD is a brain disorder that causes tremors, stiffness, and difficulty with movement due to the loss of dopamine producing cells. Current medications improve symptoms temporarily but cause side effects after prolonged use, limiting their benefits, and they do not slow or stop the disease. This has created an urgent need for new treatments that work through different biological pathways. One promising target is a protein in the brain called G protein-coupled receptor 6 (GPR6), which helps control movement and is thought to be overactive in PD. CVN424 is a new experimental drug that “turns down” GPR6 activity and is currently being tested in clinical trials as a way to improve symptoms without the side effects of classic dopamine-based drugs. However, we currently have no way to see, in a living brain, how much CVN424 actually reaches its target or how long it stays there. Positron emission tomography (PET) is a powerful imaging technique that can show where a drug goes in the body using tiny amounts of a radiopharmaceutical. In this project, we will attach a small amount of radioactive fluorine-18 (18F) to CVN424 to create a PET tracer, [18F]CVN424, and test how it behaves in live mice. This will allow us to measure its uptake in the brain and its binding to GPR6. If successful, this tracer could speed up the development of new GPR6-targeted drugs and eventually help select and monitor patients in future clinical trials.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Xu, Wan Li
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~